← Back to Search

Alkylating agents

Cisplatin for Prostate Cancer

Phase < 1
Recruiting
Research Sponsored by University of Rochester
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histologic diagnosis of prostate cancer
Age 18 yrs or older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial is testing if a different cancer drug will work better on patients who have become resistant to the usual treatment.

Who is the study for?
This trial is for adults with prostate cancer who are resistant to castration treatments and have seen a rise in PSA levels or show asymptomatic radiographic progression while on enzalutamide. They must have previously received docetaxel, have adequate bone marrow reserve, normal neutrophil and platelet counts, and sufficient kidney function. Those with severe neuropathy, hearing loss, or unable to tolerate pre-treatment hydration are excluded.Check my eligibility
What is being tested?
The study is testing the effectiveness of Cisplatin in patients whose prostate cancer has become resistant to enzalutamide treatment. The hypothesis suggests that Cisplatin can reverse this resistance by affecting the function of the Androgen Receptor (AR) involved in tumor growth.See study design
What are the potential side effects?
Cisplatin may cause side effects such as fatigue, nausea and vomiting, kidney damage (nephrotoxicity), nerve damage (neuropathy), hearing loss (ototoxicity), low blood cell counts leading to increased infection risk, bleeding issues or anemia.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with prostate cancer.
Select...
I am 18 years old or older.
Select...
My prostate cancer is resistant to treatment, and my PSA levels are rising despite therapy.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Response to dosing differences of Cisplatin from lab and scan results
Toxicity observed with dosing differences of Cisplatin

Side effects data

From 2012 Phase 3 trial • 256 Patients • NCT01005680
51%
Neutropenia
47%
Leukopenia
46%
Nausea
43%
Vomiting
35%
Anaemia
31%
Decreased appetite
26%
Haemoglobin decreased
26%
Fatigue
25%
Constipation
25%
White blood cell count decreased
24%
Neutrophil count decreased
19%
Alanine aminotransferase increased
13%
Platelet count decreased
12%
Rash
10%
Aspartate aminotransferase increased
10%
Thrombocytopenia
9%
Blood sodium decreased
8%
Hypokalaemia
7%
Insomnia
7%
Pyrexia
6%
Hyponatraemia
6%
Blood creatinine increased
6%
Lymphopenia
6%
Diarrhoea
6%
Dyspepsia
6%
Red blood cell count decreased
6%
Cough
4%
Dizziness
2%
Bone marrow failure
1%
Ischaemic stroke
1%
Cerebral infarction
1%
Dyspnoea
1%
Pulmonary embolism
1%
Embolism venous
1%
Superior vena cava syndrome
100%
80%
60%
40%
20%
0%
Study treatment Arm
Gemcitabine Plus Cisplatin (GC)
Pemetrexed Plus Cisplatin (PC)

Trial Design

1Treatment groups
Experimental Treatment
Group I: CisplatinExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cisplatin
2013
Completed Phase 3
~1940

Find a Location

Who is running the clinical trial?

University of RochesterLead Sponsor
840 Previous Clinical Trials
534,213 Total Patients Enrolled
7 Trials studying Prostate Cancer
520 Patients Enrolled for Prostate Cancer
Roswell Park Cancer InstituteOTHER
402 Previous Clinical Trials
30,770 Total Patients Enrolled
19 Trials studying Prostate Cancer
599 Patients Enrolled for Prostate Cancer

Media Library

Cisplatin (Alkylating agents) Clinical Trial Eligibility Overview. Trial Name: NCT03275857 — Phase < 1
Prostate Cancer Research Study Groups: Cisplatin
Prostate Cancer Clinical Trial 2023: Cisplatin Highlights & Side Effects. Trial Name: NCT03275857 — Phase < 1
Cisplatin (Alkylating agents) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03275857 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has this therapeutic approach been previously evaluated in a research setting?

"Presently, 688 studies are being conducted on this intervention with 274 at Phase 3. The majority of trials for this medication take place in Shanghai; however, there are 43399 other locations involved in its research."

Answered by AI

How many individuals are actively engaging in this experiment?

"Affirmative. According to the data on clinicaltrials.gov, enrollment for this trial is currently underway; it was posted in September 2018 and last updated June 2022 with a target recruitment of 37 individuals across one site."

Answered by AI

What are the primary medical conditions for which this therapy is employed?

"This medication has proven effective in treating ovarian cancer, but can also be used to alleviate the symptoms of testicular cancers that are resistant to conventional treatments. Moreover, it may be prescribed for those with advanced directives."

Answered by AI

Are there still opportunities for people to participate in this clinical research?

"Clinicialtrials.gov reports that recruitment for this trial is still open and active, having first been posted on September 21st 2018 and last updated June 7th 2022."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Cisplatin in Castration Resistant Prostate Cancer
Deepak Sahasrabudhe 2018. "Cisplatin in Castration Resistant Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03275857.
~0 spots leftby May 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top